May 27 (Reuters) – Gilead Sciences Inc’s new
hepatitis C drug combination, which shares an active ingredient
with blockbuster Sovaldi, was recommended for marketing approval
by the European Medicines…
The post EU regulators recommend approving Gilead’s new hepatitis C drug appeared first on NASDAQ.